Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7949878 | 0.84 | HPGD (0.47) | HPGDKMT2AERCC5FEN1HTT | |
| SCHEMBL10455866 | 0.83 | HPGD (0.46) | HPGDKMT2AERCC5FEN1NPC1 | |
| SCHEMBL19278858 | 0.83 | HPGD (0.46) | HPGDKMT2AERCC5FEN1HTT | |
| SCHEMBL3869539 | 0.81 | HPGD (0.44) | HPGDERCC5FEN1HTTSMN1; SMN2 | |
| SCHEMBL29137330 | 0.81 | HPGD (0.44) | HPGDKMT2AERCC5FEN1NPC1 | |
| SCHEMBL1199962 | 0.78 | CES1 (0.50) | HPGDERCC5FEN1HTTMAPK1 | |
| SCHEMBL8914360 | 0.78 | HPGD (0.46) | HPGDERCC5FEN1HTTSMN1; SMN2 | |
| SCHEMBL29645048 | 0.78 | CES1 (0.50) | HPGDERCC5FEN1HTTMAPK1 | |
| SCHEMBL6833654 | 0.78 | ALDH1A1 (0.61) | HPGDKMT2ASMN1; SMN2MYC | |
| SCHEMBL11259732 | 0.78 | ADRB2 (0.43) | HPGDKMT2AERCC5FEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323577-B2 | Process for producing benzofuran derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-29 | — | — | US | disclosed |
| US-20060142598-A1 | Process for producing benzofuran derivative | TAWADA HIROYUKI | 2006-06-29 | — | — | US | disclosed |
| US-20040210066-A1 | Process for producing benzofuran derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-10-21 | — | — | US | disclosed |
| EP-1408036-A1 | PROCESS FOR PRODUCING BENZOFURAN DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210066-A1 | Process for producing benzofuran derivative | IWS1, HAT1, BRD1 | HPGD 416/4885KMT2A 554/4885ERCC5 3948/4885 |
| US-20060142598-A1 | Process for producing benzofuran derivative | AHR, CBR3, HAT1 | HPGD 311/4885KMT2A 417/4885ERCC5 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.